<unk>  treatment is a rapidly changing field. Several medical therapies have been proposed in the treatment of<unk> , with corticosteroid therapy being the most effective. However, corticosteroid therapy (specifically with prednisone and dexamethasone) has demonstrated limited effectiveness in some patients, suggesting the need for novel treatment methods. The goal of most<unk>  treatments is to administer corticosteroids over a certain period of time, re-evaluate hearing at each appointment, and eventually taper off corticosteroid administration. Ideally, patients can be tapered off with hearing fully recovered, though this is the least likely outcome. Often, tumor necrosis factor-α (TNF-α) inhibitors must be administered alongside corticosteroids to achieve a favorable outcome and eventual end to corticosteroid treatment. Recent papers have indicated that the TNF-α inhibitor, infliximab, has the potential to allow for sustained patient improvement and alleviation of symptoms. Cytotoxic agents such as cyclophosphamide and methotrexate have been used in<unk>  treatment in the past; however, findings have suggested limited symptom alleviation from these drugs.
Autoimmune inner ear disease
Neuroendocrine adenoma middle ear
Noise-induced hearing loss
Labyrinthine fistula
Vibroacoustic disease
Vestibular adenitis
Red ear syndrome
Optic nerve tumor